India
Oncology · 4 min read

Multiple endocrine neoplasia type 4

Learn about Multiple endocrine neoplasia type 4, its reported features, relevant specialists, and questions to discuss at a medical consultation.

Also known as: MEN4

Compiled from public sources
Text selected and arranged from Orphanet. It describes the condition as those sources do; it has not been rewritten for India.
01 Oct 2026
Not medically reviewed
No registered doctor has reviewed this page. Use it to decide who to see and what to ask — not to diagnose or treat.
—
This is not medical advice. If symptoms are severe, sudden or getting worse, call 112 (or 108 for an ambulance) or go to the nearest emergency department.

The sources compiled here do not cover: diagnosis, treatment, prevention, prognosis, prevalence. Ask the treating doctor about these.

What it is

From: Orphanet

Multiple endocrine neoplasia type 4 (MEN4) is a very rare form of MEN, an inherited cancer syndrome, characterized by parathyroid and anterior pituitary tumors, possibly associated with adrenal, renal, and reproductive organ tumors.

Reported clinical features and what the terms mean

The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.

The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.

Abnormality of the endocrine system · Very frequent (99-80%)
An abnormality of the endocrine system.
Elevated circulating parathyroid hormone level · Very frequent (99-80%)
An abnormal increased concentration of parathyroid hormone.
Hypercalcemia · Very frequent (99-80%)
The concentration of calcium in the blood circulation is above the upper limit of normal.
Hyperparathyroidism · Very frequent (99-80%)
Excessive production of parathyroid hormone (PTH) by the parathyroid glands.
Parathyroid adenoma · Very frequent (99-80%)
A benign tumor of the parathyroid gland that can cause hyperparathyroidism.
Parathyroid hyperplasia · Very frequent (99-80%)
Hyperplasia of the parathyroid gland.
Abnormality of pancreas physiology · Frequent (79-30%)
An anomaly of the function of the pancreas.
Adrenocortical adenoma · Frequent (79-30%)
Adrenocortical adenomas are benign tumors of the adrenal cortex.
Angiofibromas · Frequent (79-30%)
Angiofibroma consist of many often dilated vessels.
Diarrhea · Frequent (79-30%)
Abnormally increased frequency (usually defined as three or more) loose or watery bowel movements a day.
Elevated circulating growth hormone concentration · Frequent (79-30%)
Acromegaly is a condition resulting from overproduction of growth hormone by the pituitary gland in persons with closed epiphyses, and consists chiefly in the enlargement of the distal parts of the body. The circumference of the skull increases, the nose becomes broad, the tongue becomes enlarged, the facial features become coarsened, the mandible grows excessively, and the teeth become separated. The fingers and toes grow chiefly in thickness.
Episodic abdominal pain · Frequent (79-30%)
An intermittent form of abdominal pain.
Esophagitis · Frequent (79-30%)
Inflammation of the esophagus.
Fasting hyperinsulinemia · Frequent (79-30%)
An increased concentration of insulin in the blood in the fasting state, i.e., not as the response to food intake.

Other findings in the same source

From: Orphanet

Additional reported features include Hyperinsulinemic hypoglycemia (Frequent (79-30%)); Insulinoma (Frequent (79-30%)); Neuroendocrine neoplasm (Frequent (79-30%)); Peptic ulcer (Frequent (79-30%)); Pituitary adenoma (Frequent (79-30%)); Pituitary growth hormone cell adenoma (Frequent (79-30%)); Pituitary null cell adenoma (Frequent (79-30%)); Pituitary prolactin cell adenoma (Frequent (79-30%)); Pulmonary carcinoid tumor (Frequent (79-30%)); Renal angiomyolipoma (Frequent (79-30%)). This is a selected summary, not a complete description of the condition.

When it may begin

From: Orphanet

Adult

Inheritance in the source

From: Orphanet

Autosomal dominant; Not applicable

Which doctor should you see?

The suggested department for discussing Multiple endocrine neoplasia type 4 is Oncology, with a oncologist and relevant organ specialist as the relevant type of clinician. General physician / Family Medicine; paediatrician for children. Referral depends on symptoms.

Additional services that may be relevant, depending on the findings, include: Clinical Genetics; Relevant organ specialist / Surgical Oncology as indicated.

This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.

How to prepare for an assessment

Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.

Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.

  • Has the exact tumour type been confirmed, and is staging relevant?
  • What is the goal of each proposed treatment option?
  • How will side effects, daily function and supportive care be addressed?

Treatment discussions and follow-up

The material gathered for this draft does not provide a complete condition-specific treatment pathway for Multiple endocrine neoplasia type 4. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.

Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.

The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.

When to seek emergency help

Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.

Find a doctor for Multiple endocrine neoplasia type 4

Oncology is not listed separately on The Doctor Index; the nearest speciality is medical oncology. Every profile shows the doctor’s registration and what has been checked.

All oncology conditions →

Sources

Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.

General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-1615.